Literature DB >> 8120852

Pregnancy outcome after expectant management of premature rupture of the membranes in the second trimester.

J U Hibbard1, M C Hibbard, M Ismail, E Arendt.   

Abstract

Because management of premature rupture of the membranes (PROM) at or before 26 weeks is controversial, we examined maternal and perinatal outcome after expectant management of 44 pregnancies complicated by this problem. Mean gestational age at preterm PROM was 23.9 +/- 1.7 (SD) weeks. The latency period between preterm PROM and delivery ranged from 1 to 68 days, with a medium of 6. Of the patients, 54.6% delivered within a week of PROM, and 79.5% delivered by four weeks; 77.2% developed chorioamnionitis, but despite this high incidence, there was no maternal sepsis or pelvic thrombophlebitis, and no maternal surgery was necessary. Perinatal outcome was 60.5% neonatal survival, 54.2% perinatal survival and a stillbirth rate of 10.4%. Respiratory distress syndrome, bronchopulmonary dysplasia, sepsis and intraventricular hemorrhage were common types of neonatal morbidity. There was no pulmonary hypoplasia, and limb deformity was seen in only two neonates. Costs of expectant management in pregnancies complicated by second-trimester PROM were estimated, and a strategy to reduce cost is suggested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8120852

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Association between preterm delivery and bacterial vaginosis with or without treatment.

Authors:  Masao Shimaoka; Yoshie Yo; Kunihiko Doh; Yasushi Kotani; Ayako Suzuki; Isao Tsuji; Masaki Mandai; Noriomi Matsumura
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

2.  Child outcomes after amnioinfusion compared with no intervention in women with second-trimester rupture of membranes: a long-term follow-up study of the PROMEXIL-III trial.

Authors:  A A de Ruigh; N E Simons; J van 't Hooft; A S van Teeffelen; R G Duijnhoven; A G van Wassenaer-Leemhuis; C Aarnoudse-Moens; C van de Beek; D Oepkes; M C Haak; M Woiski; M M Porath; J B Derks; Lem van Kempen; T J Roseboom; B W Mol; E Pajkrt
Journal:  BJOG       Date:  2020-03-04       Impact factor: 7.331

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.